×
About 2,970 results

ALLMedicine™ Cluster Headache Center

Research & Reviews  766 results

Self-Reported Efficacy of Treatments in Cluster Headache: a Systematic Review of Survey...
https://doi.org/10.1007/s11916-022-01063-5 10.1016/S1474-4422(17)30405-2 10.1177/0333102419867280 10.1111/head.12866 10.1038/nrneurol.2016.134 10.1136/practneurol-2018-002124 10.1007/s40263-019-00696-2 10.1046/j.1468-2982.2000.00026.x 10.1177/0333102410363490 10.1136/jnnp-2018-320113 10.1111/ner.12869 10.1007/s11916-004-0030-z 10.1016/j.ctim.2007.05.002 10.1177/0333102412458190 10.3109/02813432.2014.944410 10.1007/s11916-014-0413-8 10.1111/head.13516 10.1111/head.14063 10.1111/j.1526-4610.1990.hed3007411.x 10.1212/01.WNL.0000046589.45855.30 10.1001/jama.2009.1855 10.1111/j.1600-0404.1993.tb04189.x 10.1093/bja/aen103 10.2217/pmt-2017-0049 10.1017/ice.2016.171 10.1111/j.1526-4610.2006.00534.x 10.1177/0333102415583145 10.1080/02791072.2015.1107664 10.1177/0333102418804160 10.1111/head.13295 10.1111/head.13473 10.1093/nar/gkw419 10.1080/1355621021000005937 10.1111/j.1755-5949.2008.00059.x 10.3389/fphar.2018.00177 10.1186/s12982-015-0037-4 10.1016/j.shpsc.2011.07.003 10.1007/s13194-017-0169-1 10.1093/bjps/axw008 10.3389/fncir.2014.00052 10.1177/0333102412452044 10.1007/s13311-020-00962-y 10.1021/acs.jnatprod.9b01061
Current Pain and Headache Reports; Rusanen SS, De S et. al.

Jun 28th, 2022 - The use and efficacy of various substances in the treatment of CH have been studied in several retrospective surveys. The aim of the study is to systematically review published survey studies to evaluate the reported efficacies of both established...

A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks
https://clinicaltrials.gov/ct2/show/NCT02655523

Jun 23rd, 2022 - Greater occipital nerve (GON) injection is a commonly performed diagnostic and therapeutic procedure in headache patients. GON blocks have been shown to be effective in the treatment of a variety of headaches including occipital neuralgia, migrain...

Eptinezumab in Participants With Episodic Cluster Headache
https://clinicaltrials.gov/ct2/show/NCT04688775

Jun 21st, 2022 - Eligible participants will be randomly assigned to receive treatment, in a blinded manner, two infusions of either eptinezumab or placebo in a cross-over manner during the Placebo-controlled Period and Active Treatment Period of the study. The tot...

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
https://clinicaltrials.gov/ct2/show/NCT05064397

Jun 16th, 2022 - The participants who take part in this trial will be asked to stay in the trial for about a year. The participants will be asked to visit the trial site 7 times during the trial. In between trial site visits, they will have scheduled phone calls w...

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
https://clinicaltrials.gov/ct2/show/NCT04066023

Jun 14th, 2022 - This is a randomized, double-blinded, placebo-controlled study. Approximately 120 subjects who meet the entry criteria will be randomized 1:1:1 to receive one of three blinded treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x ...

see more →

Drugs  171 results see all →

Clinicaltrials.gov  99 results

A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks
https://clinicaltrials.gov/ct2/show/NCT02655523

Jun 23rd, 2022 - Greater occipital nerve (GON) injection is a commonly performed diagnostic and therapeutic procedure in headache patients. GON blocks have been shown to be effective in the treatment of a variety of headaches including occipital neuralgia, migrain...

Eptinezumab in Participants With Episodic Cluster Headache
https://clinicaltrials.gov/ct2/show/NCT04688775

Jun 21st, 2022 - Eligible participants will be randomly assigned to receive treatment, in a blinded manner, two infusions of either eptinezumab or placebo in a cross-over manner during the Placebo-controlled Period and Active Treatment Period of the study. The tot...

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
https://clinicaltrials.gov/ct2/show/NCT05064397

Jun 16th, 2022 - The participants who take part in this trial will be asked to stay in the trial for about a year. The participants will be asked to visit the trial site 7 times during the trial. In between trial site visits, they will have scheduled phone calls w...

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches
https://clinicaltrials.gov/ct2/show/NCT04066023

Jun 14th, 2022 - This is a randomized, double-blinded, placebo-controlled study. Approximately 120 subjects who meet the entry criteria will be randomized 1:1:1 to receive one of three blinded treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x ...

The Will Erwin Headache Research Center - Cluster Headache Study
https://clinicaltrials.gov/ct2/show/NCT02910323

May 25th, 2022 - The Will Erwin Headache Research Center will assemble a national registry of Cluster Headache patients and will sub-categorize and organize this cohort based on individuating characteristics including but not limited to type and severity of condit...

see more →

News  150 results

Neuropeptide-Induced Cluster Headache Attacks Not Tied to CGRP Changes
https://www.medscape.com/viewarticle/968494

Feb 15th, 2022 - Cluster headache attacks induced by either pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) or vasoactive intestinal polypeptide (VIP) do not lead to changes in plasma levels of calcitonin gene-related peptide (CGRP) or markers of m...

PACAP38- and VIP-induced cluster headache attacks do not appear to alter CGRP levels
https://www.mdedge.com/neurology/article/251757/headache-migraine/pacap38-and-vip-induced-cluster-headache-attacks-do-not
Steve Cimino

Feb 14th, 2022 - Cluster headache attacks induced by either pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) or vasoactive intestinal polypeptide (VIP) do not lead to changes in plasma levels of calcitonin gene-related peptide (CGRP) or markers of m.

Intranasal Ketamine Effective in Cluster Headache
https://www.medscape.com/viewarticle/966922

Jan 20th, 2022 - Intranasal ketamine may be a viable treatment option for acute cluster headache attacks, a pilot study has found, though it did not reduce pain intensity as quickly as initially anticipated. "In clinical practice, intranasal ketamine might be a va...

Ketamine nasal spray provides slow-acting relief for cluster headache attacks
https://www.mdedge.com/neurology/article/250915/headache-migraine/ketamine-nasal-spray-provides-slow-acting-relief-cluster
Steve Cimino

Jan 19th, 2022 - Intranasal ketamine may be a viable treatment option for acute cluster headache attacks, a pilot study has found, though it did not reduce pain intensity as quickly as initially anticipated. “In clinical practice, intranasal ketamine might be a va.

Woman with throbbing unilateral headache
https://www.mdedge.com/migraine-challenge-center/article/250911/migraine/woman-throbbing-unilateral-headache

Jan 19th, 2022 - Migraine is a complex disorder characterized by recurrent episodes of headache, most often unilateral and in some cases associated with photophobia or phonophobia — a constellation known as aura — that usually arises before the head pain but may a.

see more →

Patient Education  2 results see all →